Enveric Biosciences, Inc. ENVB
We take great care to ensure that the data presented and summarized in this overview for Enveric Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ENVB
Top Purchases
Top Sells
About ENVB
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Insider Transactions at ENVB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 09
2024
|
George A. Kegler |
BUY
Grant, award, or other acquisition
|
Direct |
47,733
+49.83%
|
-
|
|
Oct 09
2024
|
Sheila De Witt |
BUY
Grant, award, or other acquisition
|
Direct |
27,845
+50.0%
|
-
|
|
Oct 09
2024
|
Michael D Webb |
BUY
Grant, award, or other acquisition
|
Direct |
47,733
+50.0%
|
-
|
|
Oct 09
2024
|
Marcus Schabacker |
BUY
Grant, award, or other acquisition
|
Direct |
47,733
+49.83%
|
-
|
|
Oct 09
2024
|
Joseph Edward Tucker CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
161,633
+32.49%
|
-
|
|
Oct 09
2024
|
Frank Pasqualone |
BUY
Grant, award, or other acquisition
|
Direct |
47,733
+49.48%
|
-
|
|
Oct 09
2024
|
Kevin Michael Coveney CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+34.9%
|
-
|
|
Oct 09
2024
|
Peter J. Facchini CHIEF INNOVATION OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+23.41%
|
-
|
|
Feb 22
2024
|
Joseph Edward Tucker CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+36.47%
|
-
|
|
Feb 22
2024
|
Peter J. Facchini CHIEF INNOVATION OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+35.5%
|
-
|
|
Feb 22
2024
|
Kevin Michael Coveney CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+40.96%
|
-
|
|
Sep 15
2023
|
Frank Pasqualone |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$2,000
$2.14 P/Share
|
|
Mar 13
2023
|
Kevin Michael Coveney CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
26,500
+50.0%
|
-
|
|
Jan 25
2023
|
Joseph Edward Tucker CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
44,000
+37.23%
|
-
|
|
Jan 25
2023
|
Avani Kanubaddi President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+17.14%
|
-
|
|
Jan 25
2023
|
Jillian Marie Hagel Vice President of Innovation |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+25.1%
|
-
|
|
Jan 25
2023
|
Peter J. Facchini CHIEF INNOVATION OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,000
+29.38%
|
-
|
|
Oct 13
2021
|
Joseph Edward Tucker CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
16,374
+20.74%
|
-
|
|
Oct 13
2021
|
Peter J. Facchini CHIEF INNOVATION OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
11,521
+18.83%
|
-
|
|
Oct 13
2021
|
Jillian Marie Hagel Vice President of Innovation |
BUY
Grant, award, or other acquisition
|
Direct |
11,521
+18.87%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 730K shares |
|---|